Vasopressin Analog DDAVP in the Treatment of Diabetes Insipidus

Wai Nang P Lee, Barbara M. Lippe, Stephen Lafranchi, Solomon A. Kaplan

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A synthetic vasopressin analog, 1-desamino-8D-arginine vasopressin (DDAVP also known as desmopressin), was found to be highly effective in the treatment of seven children and one adult with vasopressin-sensitive diabetes insipidus. The average duration of action of DDAVP was 10 to 11 hours, and with proper adjustment of dose, the subjects were able to control their symptoms satisfactorily with one or two inhalations daily. The youngest child in whom adequate control was achieved was 2 years of age. All subjects found the use of intranasal DDAVP superior to other forms of therapy, and none experienced any known side-effects after six months of treatment. All subjects in this study are currently using 2.5μg to 10μg of DDAVP once or twice daily.

Original languageEnglish (US)
Pages (from-to)166-169
Number of pages4
JournalAmerican Journal of Diseases of Children
Volume130
Issue number2
DOIs
StatePublished - 1976
Externally publishedYes

Fingerprint

Deamino Arginine Vasopressin
Diabetes Insipidus
Vasopressins
Therapeutics
Arginine Vasopressin
Inhalation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Vasopressin Analog DDAVP in the Treatment of Diabetes Insipidus. / Lee, Wai Nang P; Lippe, Barbara M.; Lafranchi, Stephen; Kaplan, Solomon A.

In: American Journal of Diseases of Children, Vol. 130, No. 2, 1976, p. 166-169.

Research output: Contribution to journalArticle

Lee, Wai Nang P ; Lippe, Barbara M. ; Lafranchi, Stephen ; Kaplan, Solomon A. / Vasopressin Analog DDAVP in the Treatment of Diabetes Insipidus. In: American Journal of Diseases of Children. 1976 ; Vol. 130, No. 2. pp. 166-169.
@article{8fb8b5bcd4a6471a9203125b9dba65a1,
title = "Vasopressin Analog DDAVP in the Treatment of Diabetes Insipidus",
abstract = "A synthetic vasopressin analog, 1-desamino-8D-arginine vasopressin (DDAVP also known as desmopressin), was found to be highly effective in the treatment of seven children and one adult with vasopressin-sensitive diabetes insipidus. The average duration of action of DDAVP was 10 to 11 hours, and with proper adjustment of dose, the subjects were able to control their symptoms satisfactorily with one or two inhalations daily. The youngest child in whom adequate control was achieved was 2 years of age. All subjects found the use of intranasal DDAVP superior to other forms of therapy, and none experienced any known side-effects after six months of treatment. All subjects in this study are currently using 2.5μg to 10μg of DDAVP once or twice daily.",
author = "Lee, {Wai Nang P} and Lippe, {Barbara M.} and Stephen Lafranchi and Kaplan, {Solomon A.}",
year = "1976",
doi = "10.1001/archpedi.1976.02120030056010",
language = "English (US)",
volume = "130",
pages = "166--169",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Vasopressin Analog DDAVP in the Treatment of Diabetes Insipidus

AU - Lee, Wai Nang P

AU - Lippe, Barbara M.

AU - Lafranchi, Stephen

AU - Kaplan, Solomon A.

PY - 1976

Y1 - 1976

N2 - A synthetic vasopressin analog, 1-desamino-8D-arginine vasopressin (DDAVP also known as desmopressin), was found to be highly effective in the treatment of seven children and one adult with vasopressin-sensitive diabetes insipidus. The average duration of action of DDAVP was 10 to 11 hours, and with proper adjustment of dose, the subjects were able to control their symptoms satisfactorily with one or two inhalations daily. The youngest child in whom adequate control was achieved was 2 years of age. All subjects found the use of intranasal DDAVP superior to other forms of therapy, and none experienced any known side-effects after six months of treatment. All subjects in this study are currently using 2.5μg to 10μg of DDAVP once or twice daily.

AB - A synthetic vasopressin analog, 1-desamino-8D-arginine vasopressin (DDAVP also known as desmopressin), was found to be highly effective in the treatment of seven children and one adult with vasopressin-sensitive diabetes insipidus. The average duration of action of DDAVP was 10 to 11 hours, and with proper adjustment of dose, the subjects were able to control their symptoms satisfactorily with one or two inhalations daily. The youngest child in whom adequate control was achieved was 2 years of age. All subjects found the use of intranasal DDAVP superior to other forms of therapy, and none experienced any known side-effects after six months of treatment. All subjects in this study are currently using 2.5μg to 10μg of DDAVP once or twice daily.

UR - http://www.scopus.com/inward/record.url?scp=0017030570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017030570&partnerID=8YFLogxK

U2 - 10.1001/archpedi.1976.02120030056010

DO - 10.1001/archpedi.1976.02120030056010

M3 - Article

VL - 130

SP - 166

EP - 169

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 2

ER -